Please login to the form below

Not currently logged in

Daiichi Sankyo promotes Dr Marielle Cohard-Radice

She becomes executive vice president, global head of development

Daiichi Sankyo Dr Marielle Cohard-RadiceDaiichi Sankyo has promoted Dr Marielle Cohard-Radice to executive vice president, global head of development.

Based out of the pharmaceutical firm's Edison, New Jersey office, Dr Marielle Cohard-Radice will take on responsibility for the development strategy and portfolio planning for the cardiovascular-metabolism and internal medicine therapeutic areas.

Dr Cohard-Radice most recently served as vice president of clinical development operation for Daiichi Sankyo's Pharma Development business, as well as serving as the company's managing director for European development.

Prior to joining Daiichi Sankyo in 2012, Dr Cohard-Radice held senior leadership positions at Axcan Pharma, Novartis, Merck & Co and Schering-Plough Research Institute.

Dr Glenn Gormley, senior executive officer and global head, research and development at Daiichi Sankyo, said: “Dr Cohard-Radice brings more than 25 years of experience and success in the global development of medicines.

“Marielle is a proven leader who simultaneously drives accountability and collaboration across global teams, always with a keen focus on the needs of patients.”

Meanwhile, Dr Cohard-Radice's predecessor Dr Mahmoud Ghazzi, the former global head of development, has left the company.

Dr Gormley added: “Dr Ghazzi's contributions at Daiichi Sankyo are most appreciated and we wish him all the best in his new endeavours.”

7th September 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?